Key Takeaways

  • Reckitt (LSE: RKT) was quoted at 5,004.00p in early trading on 22 July 2026, up 0.89%, having fallen 2.57% the prior session, so the move captures an intraday snapshot rather than a sustained rally.
  • Full-year 2025 results (5 March 2026) showed like-for-like group revenue up 5% to £14.21bn and adjusted operating profit up 5.3% at constant currency to £3.54bn.
  • The first-quarter 2026 update (22 April 2026) was softer, with core like-for-like sales up just 1.3% as a weak cold and flu season weighed; management kept full-year guidance of 4-5% core growth.
  • Strategic simplification continues: the Essential Home business was sold to Advent International for $4.8bn in December 2025, and the Mead Johnson nutrition unit is earmarked for disposal.
  • Material risks remain, including European weakness, seasonal exposure, input-cost pressure from higher oil prices and reported US litigation tied to Mead Johnson.

Reckitt Benckiser Group plc (LSE: RKT)

Reckitt Benckiser Group plc is a FTSE 100 consumer-health and hygiene business headquartered in Slough. Its portfolio spans household names such as Dettol, Durex, Nurofen, Strepsils, Vanish, Gaviscon and Finish, alongside the Mead Johnson infant-nutrition brands including Enfamil.

The group organises itself around health, hygiene and nutrition, and has increasingly framed its strategy around a smaller set of higher-margin "power brands". Chief executive Kris Licht has led a programme to concentrate the portfolio on these core franchises while exiting lower-growth or non-core activities.

As at the 22 July 2026 session, Reckitt's market capitalisation stood at roughly £31.8bn, on about 635 million shares in issue. The stock is widely held by UK income funds, reflecting its long record as a dependable dividend payer.

What Is Driving the Latest Move in Reckitt Shares?

The verified data point is modest and specific: Reckitt changed hands at 5,004.00p at 08:22 on 22 July 2026, a rise of 0.89% on the day. Crucially, this uptick followed a decline — on 21 July 2026 the shares closed at 4,938.00p, down 2.57% on that session. The 22 July move therefore reads as a partial recovery rather than a decisive breakout.

No single company announcement has been confirmed as the driver of the early-morning gain. The broader context is a rotation back towards defensive, cash-generative consumer staples at a time of geopolitical uncertainty. UK inflation data that week showed the June figure easing to 2.6%, and the FTSE 100 was trading close to record territory.

In short, the rise appears sentiment-led rather than event-led, and should be treated as a single-session data point.

Confirmed News and Market Catalysts

  • Full-year 2025 results (5 March 2026). Reckitt reported solid fourth-quarter momentum and lifted its dividend.
  • Essential Home disposal (December 2025). The group sold a majority stake in its Essential Home business to private equity firm Advent International for $4.8bn, a key step in its simplification plan.
  • First-quarter 2026 update (22 April 2026). Trading softened as a weak seasonal cold and flu period hit sales, though full-year guidance was reiterated.
  • Special dividend. A 235p special dividend was paid in February 2026, funded in part by divestment proceeds.
  • Share buyback. A regulatory filing on 16 June 2026 confirmed the completion of a share buyback programme.

Recent Financial and Operational Performance

The FY2025 numbers, published on 5 March 2026, were the most substantial recent disclosure. Like-for-like group revenue rose 5% to £14.21bn, with price/mix contributing 4.1% and volumes adding 0.9%. Core Reckitt revenue increased 5.2% to £10.23bn, while reported revenue edged up just 0.3%, reflecting currency headwinds and disposal effects.

Profitability held up well. Adjusted operating profit grew 5.3% at constant currency to £3.54bn, with the operating margin widening 40 basis points to 24.9%. Adjusted diluted earnings per share ticked up 1.1% to 352.8p, and the full-year ordinary dividend was raised 5% to 212.2p.

Geographically, the standout was developing markets, where sales jumped 17.2% on double-digit growth in China and India. Europe, by contrast, fell 4.5% amid tougher category conditions, while North America returned to growth of 2.5%.

The first quarter of 2026 then reminded investors of the group's seasonal sensitivity. Core like-for-like sales rose only 1.3%, with Europe down 4.2% and North America down 0.9%, partially offset by a 7.6% rise in emerging markets. Management attributed the softness to very low seasonal incidence, weak categories in Europe and geopolitical disruption, and kept full-year guidance for core like-for-like growth of 4-5%.

Industry and Economic Backdrop

Reckitt operates in consumer health and hygiene, categories usually prized for their resilience across the economic cycle. When investors turn cautious, such defensive staples can attract renewed interest, a dynamic that has been noted in mid-2026.

The macro picture is mixed. UK consumer price inflation cooled to 2.6% in June 2026, a helpful signal for household budgets. At the same time, heightened tensions in the Middle East and firmer oil prices raise the risk of cost inflation for a manufacturer reliant on packaging, transport and raw materials.

Reckitt has flagged that if oil prices stay elevated, its costs would rise, though it expects this to be largely offset by supply-chain flexibility, hedging and pricing. That is guidance from management rather than a guaranteed outcome.

What Could Drive Reckitt Shares Higher?

  • Completion of the Mead Johnson disposal. A clean, well-priced exit would sharpen the portfolio and could remove an overhang.
  • A stronger cold and flu season. With Q1 dented by low seasonal incidence, a more normal season later in 2026 would flatter comparatives.
  • Continued emerging-market momentum. Double-digit growth in China and India, if sustained, offsets European softness.
  • Capital returns. A rising ordinary dividend, the recently completed buyback and the February 2026 special dividend point to a shareholder-friendly capital policy.
  • Defensive rotation. In uncertain markets, staples with dependable cash flows can attract renewed investor interest.

Principal Risks and Downside Factors

  • European weakness. Sales in Europe fell in both the FY2025 period and Q1 2026, and a turnaround is not yet evident.
  • Seasonal sensitivity. A weak cold and flu season can materially dent quarterly growth, as Q1 2026 showed.
  • Input-cost inflation. Elevated oil prices and geopolitical disruption could pressure margins if hedging and pricing prove insufficient.
  • Execution risk on disposals. The Mead Johnson sale is not yet complete, and timing or price could disappoint.
  • Litigation. Reckitt's Mead Johnson infant-formula business has been the subject of product-liability litigation in the United States. Investors should follow official company disclosures for the current status.
  • Currency. As a global business, reported results are exposed to swings in sterling against the dollar and emerging-market currencies.

Valuation: Is Reckitt (LSE: RKT) Fairly Priced?

Reckitt has traded on a trailing price-to-earnings multiple of roughly 13.6 times, with a dividend yield in the region of 4%. Those metrics sit below the loftier ratings the shares once commanded, reflecting several years during which growth disappointed and portfolio and litigation concerns weighed on sentiment.

Whether that represents value or a value trap depends on execution. If Reckitt can deliver its guided 4-5% core growth, complete the Mead Johnson exit and defend margins, the current rating could look undemanding for a high-quality staples business. If European weakness persists or costs climb, the shares may struggle to re-rate.

Balanced Outlook

Reckitt enters the second half of 2026 as a work in progress. The FY2025 results demonstrated resilient revenue growth, margin expansion and healthy capital returns, while the Q1 2026 update exposed the group's continuing vulnerability to seasonal and regional softness.

The strategic direction, concentrating on core power brands and exiting non-core units, is coherent, but its success hinges on completing the Mead Johnson disposal on acceptable terms and on reviving European performance. The 22 July share-price uptick is best read as a modest, sentiment-driven move within a still-unresolved turnaround story.